Pim kinase inhibitors (Abbott)

N/A

Report date: 2025/03/20 20:00:06

NME

Base Information

Drug NamePim kinase inhibitors (Abbott)

Drug Alias NameN/A

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionSerine/threonine-protein kinase pim-2 inhibitorsSerine/threonine-protein kinase pim-3 inhibitorsProto-oncogene serine/threonine-protein kinase Pim-1 inhibitors

TargetsSerine/threonine-protein kinase pim-2Serine/threonine-protein kinase pim-3Proto-oncogene serine/threonine-protein kinase Pim-1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAbbott Laboratories

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAbbott Laboratories

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A